2016;229:R99115
If you are considering GHK-Cu or other peptide therapies, understanding your baseline inflammatory state and genetic predispositions can support a more personalized safety assessment
Retrieved from Bhutani, S., Kahn, E., Tasali, E., & Schoeller, D
The starting dose is just the first step
In vitro experiments confirmed that A 25-35 treatment significantly inhibited the activation of the NRF2/SLC7A11/GPX4 signaling pathway in HT22 cells, upregulated the expression of Fe 2+ , TFR1, ACSL4, MDA, and GSSG, and decreased the expression of FTH1, SOD, and GSH, as well as the GSH/GSSG ratio, resulting in dysregulated neuronal iron metabolism, impaired amino acid antioxidant systems, mitochondrial dysfunction, and ferroptosis, which ultimately promoted neuronal injury
Frequently Asked Questions How much bacteriostatic water do I use to reconstitute a 10 mg peptide